查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2065170

數位生物標記市場預測至2034年—按類型、資料收集方法、技術、臨床實踐、應用、最終用戶和地區分類的全球分析

Digital Biomarkers Market Forecasts to 2034 - Global Analysis By Type, Data Collection Method, Technology, Clinical Practice, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球數位生物標記市場預計將在 2026 年達到 31 億美元，到 2034 年達到 194 億美元，在預測期內以 25.8% 的複合年成長率成長。

數位生物標記是指透過穿戴式裝置、智慧型手機、植入式裝置和遠端感測器等數位裝置收集的客觀、可量化的生理或行為數據，用於測量、解釋或預測健康相關結果。與需要對生物檢體進行實驗室分析的傳統生物標記不同，數位生物標記可透過連續的數位測量平台被動或主動地獲取，並使用人工智慧和機器學習演算法進行分析。

製藥業對利用數位生物標記的臨床試驗投入不斷增加

製藥和生物技術公司正日益將數位生物標記整合到臨床試驗方案中，以實現更靈敏、更連續、更經濟高效的療效評估。傳統的試驗終點依賴不定期的訪視和臨床醫生的主觀評估，而如今，基於穿戴式感測器數據的客觀數字終點正在被補充或取代，從而帶來更高的統計效力和更豐富的機制洞察。包括FDA和EMA在內的監管機構正積極與臨床試驗贊助者合作，透過合格評估指導計畫開發新型數位試驗終點。縮短臨床試驗週期、最佳化受試者選擇以及更全面地展現治療效果等潛在優勢，正推動製藥業對數位生物標記的開發和檢驗項目進行大量投資。

新型數位終點的不確定性路徑和臨床檢驗標準

儘管業界對新型數位生物標記作為臨床試驗終點的興趣日益濃厚，但缺乏明確的監管合格流程，這嚴重阻礙了其市場發展。申辦方在檢驗數字終點以提交監管申請所需的證據標準方面面臨不確定性，包括數據量、分析方法合格要求以及患者人群代表性標準。進行廣泛的分析檢驗研究以確定新型數字終點的合格，其複雜性和高成本可能會阻礙投資，尤其是對於資源有限的中小型生物技術公司。監管機構之間指南的差異進一步增加了全球藥物研發計畫的複雜性，並減緩了檢驗的數位生物標記被納入主流臨床試驗設計的速度。

將數位生物標記與精準醫療和伴隨診斷項目結合

將數位生物標記與基因組分析、分子診斷和伴隨診斷項目相結合，為製藥、診斷和數位健康公司提供了一個高價值的融合機會。數位生物標記能夠長期持續監測表現型對治療的反應，為遺傳和分子預測標記提供補充證據，從而在精準腫瘤學、神經病學和循環系統計畫中實現更全面的患者分層。數位生物標記和分子生物標記的結合正日益受到關注，成為標靶治療伴隨診斷的監管申報材料。科技公司和製藥創新者正在建立策略夥伴關係，以開發這些整合的生物標記生態系統，從而在診斷、治療和數位健康的價值創造領域中佔據關鍵地位。

與數據品質、設備差異性和分析可重複性相關的挑戰。

數位生物標記數據的可靠性和可重複性從根本上取決於測量設備技術性能的一致性、分析演算法的穩健性以及數據採集協議的標準化。由於設備品牌、軟體版本和患者使用模式的不同，感測器精度的差異會導致系統性測量不一致，並影響數位生物標記資料集的可解釋性。隨著設備硬體的更新換代或病患行為模式超出訓練資料集的分佈範圍，分析演算法的效能可能會隨時間推移而下降。目前缺乏數位生物標記設備性能認證的標準化測量框架，阻礙了跨中心資料聚合和研究間的可比性，限制了數位生物標記證據在監管審查和薈萃分析應用中的效用。

新冠疫情的影響：

新冠疫情大大加速了數位生物標記的研究與開發，其對遠端患者監護工具和客觀疾病進展評估方法的需求空前高漲。用於測量心率變異性、呼吸頻率和血氧飽和度的穿戴式感測器迅速應用於新冠患者監測研究和醫院監測計畫中，產生了大規模真實世界資料集，證明了數位生物標記在感染疾病管理中的效用。疫情也促進了持續遠端監測平台在醫療系統中的部署，從而產生數位生物標記數據流，拓展了真實世界證據的基礎，並提高了數位測量技術的臨床接受度。這些進展顯著加快了數位生物標記在藥物研發和臨床監測中的應用進程。

在預測期內，用於監測的生物標記預計將佔據最大的市場佔有率。

預計在預測期內，生物標記監測領域將佔據最大的市場佔有率。這反映出數位生物標記作為慢性病持續監測和治療反應追蹤的主要應用日益廣泛。醫療機構和製藥公司正在部署穿戴式裝置和基於應用程式的監測系統，以追蹤心血管疾病、神經系統疾病、糖尿病和呼吸系統疾病患者的病情進展。遠端患者監護保險報銷計劃的日益普及，為持續數位監測的部署創造了穩健的商業性框架。

預計生物標記細分市場在預測期內將呈現最高的複合年成長率。

在預測期內，預測性生物標記領域預計將呈現最高的成長率，這主要得益於製藥業加大投資，利用數位訊號預測治療反應、疾病進展以及精準醫療和標靶治療項目中的患者風險分層。基於多模態數位生物標記資料集訓練的機器學習模型已在多種疾病的預測中展現出良好的性能，從帕金森氏症運動功能進展到心血管事件風險分層，吸引了大量的研究和商業投資。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這主要得益於該地區領先的製藥和生物技術產業、學術界數位健康研究計畫的高密度部署，以及穿戴式遠端監測平台在臨床環境中的日益普及。美國憑藉大型製藥企業對數位生物標記臨床試驗項目的大規模投資、對數位生物標記新創企業的大力創業投資支持，以及FDA法規結構的不斷完善（該框架正逐步明確數字終點指標的合格認定流程），引領著該地區的市場主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於該地區穿戴式裝置市場的快速擴張、消費者健康科技的高滲透率，以及中國、日本、韓國和印度等市場藥物臨床試驗活動的成長。區域製藥公司正日益將數位化終點指標納入針對亞洲特有疾病患者的臨床項目和監管申報中。日本和新加坡政府的醫療創新計畫正在支持學術機構和產業合作夥伴在數位化生物標記研究方面的合作。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球數位生物標記市場：按類型分類

  • 診斷生物標記
  • 用於監測的生物標記
  • 預測性生物標記
  • 預後生物標記
  • 動態物標誌物
  • 安全生物標記

第6章 全球數位生物標記市場：依資料收集方法分類

  • 穿戴式裝置
  • 行動應用
  • 嵌入式裝置
  • 攜帶式監測設備
  • 遠端感測器

第7章 全球數位生物標記市場：依技術分類

  • 人工智慧和機器學習
  • 巨量資料分析
  • 雲端運算
  • 物聯網 (IoT)
  • 數字表現型分析
  • 區塊鏈在數位健康領域的應用

第8章 全球數位生物標記市場：按臨床領域分類

  • 心血管疾病
  • 神經病變
  • 呼吸系統疾病
  • 代謝性疾病
  • 精神和行為障礙
  • 睡眠和疲勞監測
  • 腫瘤學
  • 肌肉骨骼疾病

第9章 全球數位生物標記市場：按應用分類

  • 疾病診斷
  • 疾病監測
  • 藥物發現與開發
  • 臨床試驗
  • 個人化醫療
  • 遠端患者監護
  • 追蹤健康狀況

第10章 全球數位生物標記市場：依最終用戶分類

  • 醫療服務提供方
  • 製藥和生物技術公司
  • 研究機構
  • 付款人和保險公司
  • 病人和消費者

第11章 全球數位生物標記市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Apple Inc.
  • AliveCor Inc.
  • ActiGraph LLC
  • Empatica Inc.
  • Koneksa Health
  • Biogen Inc.
  • Huma Therapeutics
  • IXICO plc
  • Evidation Health Inc.
  • Verily Life Sciences
  • Fitbit Health Solutions
  • Altoida Inc.
  • Clario
  • Sonde Health, Inc.
  • Neurotrack Technologies, Inc.
Product Code: SMRC36777

According to Stratistics MRC, the Global Digital Biomarkers Market is accounted for $3.1 billion in 2026 and is expected to reach $19.4 billion by 2034, growing at a CAGR of 25.8% during the forecast period. Digital Biomarkers are objective, quantifiable physiological or behavioral data points collected through digital devices including wearables, smartphones, implantables, and remote sensors that are used to measure, explain, or predict health-related outcomes. Unlike traditional biomarkers requiring laboratory analysis of biological specimens, digital biomarkers are captured passively or actively through continuous digital measurement platforms and analyzed using artificial intelligence and machine learning algorithms.

Market Dynamics:

Driver:

Growing pharmaceutical industry investment in digital biomarker-enabled clinical trials

Pharmaceutical and biotechnology companies are increasingly integrating digital biomarkers into clinical trial protocols to enable more sensitive, continuous, and cost-effective outcome measurement. Traditional trial endpoints relying on infrequent clinic visits and subjective clinician assessments are being supplemented or replaced by objective digital endpoints derived from wearable sensor data, providing higher statistical power and richer mechanistic insights. Regulatory agencies including the FDA and EMA are engaging proactively with sponsors developing novel digital trial endpoints through qualification guidance programs. The potential to reduce clinical trial duration, optimize patient selection, and demonstrate therapeutic effects more comprehensively is driving substantial pharmaceutical industry investment in digital biomarker development and validation programs.

Restraint:

Regulatory pathway uncertainty and clinical validation standards for novel digital endpoints

Despite growing industry interest, the absence of clearly defined regulatory qualification pathways for novel digital biomarkers as trial endpoints represents a significant market development barrier. Sponsors face uncertainty about the evidentiary standards required to validate digital endpoints for regulatory submission, including the volume of data, analytical method qualification requirements, and patient population representativeness criteria. The complexity and cost of conducting the extensive analytical validation studies required to qualify novel digital endpoints can deter investment, particularly from smaller biotechnology companies with limited resources. Fragmented guidance across regulatory jurisdictions adds further complexity for global drug development programs, slowing the pace at which validated digital biomarkers are incorporated into pivotal clinical trial designs.

Opportunity:

Convergence of digital biomarkers with precision medicine and companion diagnostic programs

The integration of digital biomarkers with genomic profiling, molecular diagnostics, and companion diagnostic programs represents a high-value convergence opportunity for pharmaceutical, diagnostic, and digital health companies. Digital biomarkers measuring phenotypic treatment response continuously over time provide a complementary layer of evidence alongside genetic and molecular predictive markers, enabling more comprehensive patient stratification for precision oncology, neurology, and cardiology programs. Digital-molecular biomarker combinations are emerging as potential regulatory submission packages for targeted therapy companion diagnostics. Technology companies and pharmaceutical innovators are forming strategic partnerships to develop these integrated biomarker ecosystems, positioning themselves at the intersection of diagnostics, therapeutics, and digital health value creation.

Threat:

Data quality, device variability, and analytical reproducibility challenges

The reliability and reproducibility of digital biomarker data are fundamentally dependent on the technical performance consistency of the capture devices, the robustness of the analytical algorithms, and the standardization of data collection protocols. Variability in sensor accuracy across device brands, software versions, and patient usage patterns can introduce systematic measurement inconsistencies that compromise the interpretability of digital biomarker datasets. Analytical algorithm performance can degrade over time as device hardware evolves or as patient behavioral patterns shift outside the boundaries of training dataset distributions. The absence of standardized metrological frameworks for digital biomarker device performance qualification creates barriers to multi-site data aggregation and cross-study comparability, limiting the utility of digital biomarker evidence for regulatory review and meta-analytic research applications.

Covid-19 Impact:

COVID-19 substantially accelerated digital biomarker research and commercial development by creating an unprecedented demand for remote patient monitoring tools and objective disease progression assessment methods. Wearable sensors measuring heart rate variability, respiratory rate, and oxygen saturation were rapidly deployed in COVID-19 patient monitoring studies and hospital surveillance programs, generating large real-world datasets that validated the utility of digital biomarkers for infectious disease management. The pandemic also drove health system adoption of continuous remote monitoring platforms that generate digital biomarker data streams, expanding the real-world evidence base and clinical acceptance of digital measurement approaches. These developments have meaningfully accelerated the timeline for digital biomarker adoption across drug development and clinical monitoring applications.

The monitoring biomarkers segment is expected to be the largest during the forecast period

The monitoring biomarkers segment is expected to account for the largest market share during the forecast period,reflecting the dominant application of digital biomarkers in continuous chronic disease surveillance and therapeutic response tracking. Healthcare providers and pharmaceutical companies are deploying wearable and app-based monitoring systems to track disease progression in patients with cardiovascular disorders, neurological conditions, diabetes, and respiratory diseases. The growing adoption of remote patient monitoring reimbursement programs is creating a strong commercial framework for continuous digital monitoring deployment.

The predictive biomarkers segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the predictive biomarkers segment is predicted to witness the highest growth rate, driven by the pharmaceutical industry's escalating investment in using digital signals to predict therapeutic response, disease progression, and patient risk stratification for precision medicine and targeted therapy programs. Machine learning models trained on multi-modal digital biomarker datasets are demonstrating promising predictive performance for conditions ranging from Parkinson's disease motor progression to cardiac event risk stratification, attracting significant research and commercial investment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, anchored by the region's leading pharmaceutical and biotechnology industry, high density of academic digital health research programs, and growing clinical adoption of wearable remote monitoring platforms. The United States drives regional dominance through extensive investment by major pharmaceutical companies in digital biomarker clinical trial programs, strong venture capital backing for digital biomarker startups, and an evolving FDA regulatory framework that is progressively clarifying digital endpoint qualification pathways.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, supported by the region's rapidly expanding wearable device market, high consumer health technology adoption rates, and growing pharmaceutical clinical trial activity in markets including China, Japan, South Korea, and India. Regional pharmaceutical companies are increasingly incorporating digital endpoints into clinical programs targeting Asia-specific disease populations and regulatory submissions. Government health innovation programs in Japan and Singapore are supporting digital biomarker research collaborations between academic institutions and industry partners.

Key players in the market

Some of the key players in Digital Biomarkers Market include Apple Inc., AliveCor Inc., ActiGraph LLC, Empatica Inc., Koneksa Health, Biogen Inc., Huma Therapeutics, IXIC0 plc, Evidation Health Inc., Verily Life Sciences, Fitbit Health Solutions, Altoida Inc., Clario, Sonde Health Inc., and Neurotrack Technologies Inc.

Key Developments:

In February 2026, Biogen Inc. announced expanded deployment of wearable digital biomarker endpoints in its neurological clinical trial portfolio, incorporating continuous gait analysis, sleep architecture monitoring, and motor function assessment algorithms derived from wrist-worn accelerometer data. The digital endpoint program aims to provide more sensitive and continuous measurement of disease progression in patients enrolled in Alzheimer's disease and multiple sclerosis therapeutic trials.

In January 2026, Verily Life Sciences announced a new collaboration with a major pharmaceutical company to deploy its Study Watch wearable platform for continuous biomarker data collection in a cardiovascular outcomes trial. The partnership will generate longitudinal physiological biomarker datasets from thousands of enrolled participants, supporting novel digital endpoint validation efforts under FDA Biomarker Qualification Program guidance.

Types Covered:

  • Diagnostic Biomarkers
  • Monitoring Biomarkers
  • Predictive Biomarkers
  • Prognostic Biomarkers
  • Pharmacodynamic Biomarkers
  • Safety Biomarkers

Data Collection Methods Covered:

  • Wearable Devices
  • Mobile Applications
  • Implantable Devices
  • Portable Monitoring Devices
  • Remote Sensors

Technologies Covered:

  • Artificial Intelligence & Machine Learning
  • Big Data Analytics
  • Cloud Computing
  • Internet of Things (IoT)
  • Digital Phenotyping
  • Blockchain in Digital Health

Clinical Practices Covered:

  • Cardiovascular Disorders
  • Neurological Disorders
  • Respiratory Disorders
  • Metabolic Disorders
  • Psychiatric & Behavioral Disorders
  • Sleep & Fatigue Monitoring
  • Oncology
  • Musculoskeletal Disorders

Applications Covered:

  • Disease Diagnosis
  • Disease Monitoring
  • Drug Discovery & Development
  • Clinical Trials
  • Personalized Medicine
  • Remote Patient Monitoring
  • Health & Wellness Tracking

End Users Covered:

  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
  • Research Organizations
  • Payers & Insurance Companies
  • Patients & Consumers

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Biomarkers Market, By Type

  • 5.1 Diagnostic Biomarkers
  • 5.2 Monitoring Biomarkers
  • 5.3 Predictive Biomarkers
  • 5.4 Prognostic Biomarkers
  • 5.5 Pharmacodynamic Biomarkers
  • 5.6 Safety Biomarkers

6 Global Digital Biomarkers Market, By Data Collection Method

  • 6.1 Wearable Devices
  • 6.2 Mobile Applications
  • 6.3 Implantable Devices
  • 6.4 Portable Monitoring Devices
  • 6.5 Remote Sensors

7 Global Digital Biomarkers Market, By Technology

  • 7.1 Artificial Intelligence & Machine Learning
  • 7.2 Big Data Analytics
  • 7.3 Cloud Computing
  • 7.4 Internet of Things (IoT)
  • 7.5 Digital Phenotyping
  • 7.6 Blockchain in Digital Health

8 Global Digital Biomarkers Market, By Clinical Practice

  • 8.1 Cardiovascular Disorders
  • 8.2 Neurological Disorders
  • 8.3 Respiratory Disorders
  • 8.4 Metabolic Disorders
  • 8.5 Psychiatric & Behavioral Disorders
  • 8.6 Sleep & Fatigue Monitoring
  • 8.7 Oncology
  • 8.8 Musculoskeletal Disorders

9 Global Digital Biomarkers Market, By Application

  • 9.1 Disease Diagnosis
  • 9.2 Disease Monitoring
  • 9.3 Drug Discovery & Development
  • 9.4 Clinical Trials
  • 9.5 Personalized Medicine
  • 9.6 Remote Patient Monitoring
  • 9.7 Health & Wellness Tracking

10 Global Digital Biomarkers Market, By End User

  • 10.1 Healthcare Providers
  • 10.2 Pharmaceutical & Biotechnology Companies
  • 10.3 Research Organizations
  • 10.4 Payers & Insurance Companies
  • 10.5 Patients & Consumers

11 Global Digital Biomarkers Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Apple Inc.
  • 14.2 AliveCor Inc.
  • 14.3 ActiGraph LLC
  • 14.4 Empatica Inc.
  • 14.5 Koneksa Health
  • 14.6 Biogen Inc.
  • 14.7 Huma Therapeutics
  • 14.8 IXICO plc
  • 14.9 Evidation Health Inc.
  • 14.10 Verily Life Sciences
  • 14.11 Fitbit Health Solutions
  • 14.12 Altoida Inc.
  • 14.13 Clario
  • 14.14 Sonde Health, Inc.
  • 14.15 Neurotrack Technologies, Inc.

List of Tables

  • Table 1 Global Digital Biomarkers Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Digital Biomarkers Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Digital Biomarkers Market Outlook, By Diagnostic Biomarkers (2023-2034) ($MN)
  • Table 4 Global Digital Biomarkers Market Outlook, By Monitoring Biomarkers (2023-2034) ($MN)
  • Table 5 Global Digital Biomarkers Market Outlook, By Predictive Biomarkers (2023-2034) ($MN)
  • Table 6 Global Digital Biomarkers Market Outlook, By Prognostic Biomarkers (2023-2034) ($MN)
  • Table 7 Global Digital Biomarkers Market Outlook, By Pharmacodynamic Biomarkers (2023-2034) ($MN)
  • Table 8 Global Digital Biomarkers Market Outlook, By Safety Biomarkers (2023-2034) ($MN)
  • Table 9 Global Digital Biomarkers Market Outlook, By Data Collection Method (2023-2034) ($MN)
  • Table 10 Global Digital Biomarkers Market Outlook, By Wearable Devices (2023-2034) ($MN)
  • Table 11 Global Digital Biomarkers Market Outlook, By Mobile Applications (2023-2034) ($MN)
  • Table 12 Global Digital Biomarkers Market Outlook, By Implantable Devices (2023-2034) ($MN)
  • Table 13 Global Digital Biomarkers Market Outlook, By Portable Monitoring Devices (2023-2034) ($MN)
  • Table 14 Global Digital Biomarkers Market Outlook, By Remote Sensors (2023-2034) ($MN)
  • Table 15 Global Digital Biomarkers Market Outlook, By Technology (2023-2034) ($MN)
  • Table 16 Global Digital Biomarkers Market Outlook, By Artificial Intelligence & Machine Learning (2023-2034) ($MN)
  • Table 17 Global Digital Biomarkers Market Outlook, By Big Data Analytics (2023-2034) ($MN)
  • Table 18 Global Digital Biomarkers Market Outlook, By Cloud Computing (2023-2034) ($MN)
  • Table 19 Global Digital Biomarkers Market Outlook, By Internet of Things (IoT) (2023-2034) ($MN)
  • Table 20 Global Digital Biomarkers Market Outlook, By Digital Phenotyping (2023-2034) ($MN)
  • Table 21 Global Digital Biomarkers Market Outlook, By Blockchain in Digital Health (2023-2034) ($MN)
  • Table 22 Global Digital Biomarkers Market Outlook, By Clinical Practice (2023-2034) ($MN)
  • Table 23 Global Digital Biomarkers Market Outlook, By Cardiovascular Disorders (2023-2034) ($MN)
  • Table 24 Global Digital Biomarkers Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 25 Global Digital Biomarkers Market Outlook, By Respiratory Disorders (2023-2034) ($MN)
  • Table 26 Global Digital Biomarkers Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
  • Table 27 Global Digital Biomarkers Market Outlook, By Psychiatric & Behavioral Disorders (2023-2034) ($MN)
  • Table 28 Global Digital Biomarkers Market Outlook, By Sleep & Fatigue Monitoring (2023-2034) ($MN)
  • Table 29 Global Digital Biomarkers Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 30 Global Digital Biomarkers Market Outlook, By Musculoskeletal Disorders (2023-2034) ($MN)
  • Table 31 Global Digital Biomarkers Market Outlook, By Application (2023-2034) ($MN)
  • Table 32 Global Digital Biomarkers Market Outlook, By Disease Diagnosis (2023-2034) ($MN)
  • Table 33 Global Digital Biomarkers Market Outlook, By Disease Monitoring (2023-2034) ($MN)
  • Table 34 Global Digital Biomarkers Market Outlook, By Drug Discovery & Development (2023-2034) ($MN)
  • Table 35 Global Digital Biomarkers Market Outlook, By Clinical Trials (2023-2034) ($MN)
  • Table 36 Global Digital Biomarkers Market Outlook, By Personalized Medicine (2023-2034) ($MN)
  • Table 37 Global Digital Biomarkers Market Outlook, By Remote Patient Monitoring (2023-2034) ($MN)
  • Table 38 Global Digital Biomarkers Market Outlook, By Health & Wellness Tracking (2023-2034) ($MN)
  • Table 39 Global Digital Biomarkers Market Outlook, By End User (2023-2034) ($MN)
  • Table 40 Global Digital Biomarkers Market Outlook, By Healthcare Providers (2023-2034) ($MN)
  • Table 41 Global Digital Biomarkers Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 42 Global Digital Biomarkers Market Outlook, By Research Organizations (2023-2034) ($MN)
  • Table 43 Global Digital Biomarkers Market Outlook, By Payers & Insurance Companies (2023-2034) ($MN)
  • Table 44 Global Digital Biomarkers Market Outlook, By Patients & Consumers (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.